Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGTCNASDAQ:JNCENASDAQ:LJPCNASDAQ:LOGC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AJNCEJounce Therapeutics$1.88-2.6%$1.89$0.58▼$5.87$98.94M0.752.46 million shs11.60 million shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsLOGCLogicBio Therapeutics$2.07$2.06$0.26▼$3.77$68.23M4.61652,526 shsN/A7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%-2.59%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%LOGCLogicBio Therapeutics0.00%0.00%0.00%0.00%0.00%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic TechnologiesN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00LOGCLogicBio Therapeutics$5.41M12.61N/AN/A$0.48 per share4.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AJNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ALJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ALOGCLogicBio Therapeutics-$40.03M-$0.81N/AN/AN/A-246.71%-115.29%-53.01%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40JNCEJounce TherapeuticsN/A8.378.37LJPCLa Jolla PharmaceuticalN/A4.023.52LOGCLogicBio Therapeutics0.171.992.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%JNCEJounce Therapeutics80.66%LJPCLa Jolla Pharmaceutical97.06%LOGCLogicBio Therapeutics39.11%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%JNCEJounce Therapeutics6.92%LJPCLa Jolla Pharmaceutical36.30%LOGCLogicBio Therapeutics8.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableLOGCLogicBio Therapeutics6232.96 million30.29 millionNot OptionableLJPC, JNCE, AGTC, and LOGC HeadlinesSourceHeadlineRVVTF Revive Therapeutics Ltd.seekingalpha.com - March 27 at 7:29 AMLogicBio's IPO: What You Need To Knowfinance.yahoo.com - September 24 at 9:29 AMRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltduk.finance.yahoo.com - March 31 at 7:12 PMAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeuticsfinance.yahoo.com - November 16 at 5:21 PMLogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinanznachrichten.de - November 14 at 2:54 PMLogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - November 14 at 9:53 AMShort Volatility Alert: LogicBio Therapeutics, Inc.benzinga.com - November 7 at 6:30 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCORkentuckytoday.com - October 23 at 11:01 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTXmarketwatch.com - October 17 at 10:54 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, FCRD, IMRAbignewsnetwork.com - October 16 at 4:39 PMAlexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeuticsfinsmes.com - October 4 at 8:38 PMINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGCbenzinga.com - October 4 at 10:37 AMLooking Into LogicBio Therapeutics's Recent Short Interestmsn.com - October 3 at 7:50 PMLogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGCmarketwatch.com - October 3 at 2:49 PMAstraZeneca acquires local startup at 660% premiumbizjournals.com - October 3 at 2:49 PMLogicBio's stock skyrockets after buyout bid for a 667% premiumfinance.yahoo.com - October 3 at 2:49 PMAstraZeneca pays 660% premium for gene therapy firm LogicBiomsn.com - October 3 at 9:48 AMLogicBio To Be Bought By Alexion, AstraZeneca Rare Diseasenasdaq.com - October 3 at 9:48 AMAstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGCmarketwatch.com - October 3 at 9:48 AMWhy LogicBio Therapeutics Stock Is Soaring Todaymsn.com - October 3 at 9:48 AMAlexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicinefinance.yahoo.com - October 3 at 9:48 AMLogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONEfinance.yahoo.com - September 21 at 10:19 AMLogicBio Therapeutics Increuters.com - September 1 at 12:36 PMEarnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their Estimatesfinance.yahoo.com - August 18 at 11:11 AMCompany DescriptionsApplied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.LogicBio TherapeuticsNASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.